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Abstract
This  chapter  resumes  our  current  understanding  of  asthma–chronic  obstructive
pulmonary disease (COPD) overlap syndrome (ACOS), pretending to offer a compre‐
hensive approach for the practicing physician, and provides some future perspectives on
this entity.
Although different studies recognize the presence of ACOS, the detection, diagnosis, and
treatment of these patients in clinical practice are not always simple and are subject to
different interpretations. These patients are of special interest, because they are usually
excluded from clinical trials with new medications, and also represent a clinically very
important  and  quite  prevalent  population,  with  particular  characteristics:  more
respiratory symptoms, frequent exacerbations, and worse health-related quality of life.
They are also characterized by an increase in comorbidity and a greater consumption of
health care resources compared to patients with only asthma or COPD alone.
There are currently no universally accepted, validated criteria for the diagnosis of ACOS.
The differences between clinical guidelines are discussed here (GINA 2014, GEMA 2015,
and GOLD 2014). However, to obtain clear and validated criteria, we think that further
research about the underlying mechanisms is needed.
Several potential pathways that might lead to the adult presentation of ACOS are
revised. The therapeutic recommendations of the Spanish consensus guideline for
patients with overlap phenotype COPD–asthma are provided, and other possible future
therapies are discussed in this chapter.
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1. Introduction
Although different studies recognize the presence of asthma–chronic obstructive pulmonary
disease (COPD) overlap syndrome (ACOS), the detection, diagnosis, and treatment of these
patients in clinical practice are not always simple and are subject to different interpretations
and controversies. These patients are of special interest, because they are usually excluded
from clinical trials with new medications for asthma and also represent a clinically very
important and quite prevalent population, apparently with particular characteristics: more
respiratory symptoms, frequent exacerbations, and worse health-related quality of life [1–5].
They are also characterized by an increase in comorbidity and a greater consumption of health
care resources compared to patients with only asthma or COPD alone. There are currently no
universally accepted, validated criteria for the diagnosis of ACOS. Also, clinical trials are
necessary to verify the response to treatments of this group of patients.
2. Definition of ACOS
ACOS is the coexistence of two distinct diseases in the same individual: asthma and COPD.
Whether this concept is clinically relevant or not depends on its capacity to describe an entity
with differentiated pathogenic mechanisms, prognostic particularities, and potentially specific
treatment options. The recently updated Spanish COPD guidelines [6] acknowledge the
existence of a syndrome that overlaps characteristics of COPD and asthma, and it proposes a
differential treatment.
When considering how to define this entity, existing definitions of asthma and COPD should
be taken into account. The new definition of COPD according to GOLD 2014 includes subtle
changes regarding the previous definitions, integrating the findings of recent evidence [7]. For
instance, there is no longer mention of reversibility, and it emphasizes the role of exacerbations
and comorbidities. Thus, COPD is a common, preventable and treatable disorder, defined by
persistent airflow obstruction that is mostly progressive, characterized by a chronic inflam‐
matory response in the airways and lungs to noxious particles and gases; exacerbations and
comorbidities generally contribute to the severity of the disease in individual patients.
On the other hand, in 2014, GINA [8] defined asthma as “a heterogeneous disease, usually
characterized by chronic airway inflammation. It is defined by the history of respiratory
symptoms such as wheeze, shortness of breath, chest tightness and cough that vary over time
and in intensity, together with variable expiratory airflow limitation”. The similarities between
asthma and COPD definitions are obvious, but none of their features are pathognomonic, and
all of them might be present in individual patients.
For operative purposes, in 2014, GINA and GOLD published a joint document on ACOS [9].
ACOS was defined as the presence of persistent airflow limitation with several features usually
associated with asthma and others usually associated with COPD. The document presents the
characteristics of asthma and COPD listed separately and suggests that ACOS may be the
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diagnosis when a similar number of characteristics of both asthma and COPD are identified
in a given patient. The joint task force also recommends a stepwise approach to the diagnosis.
It uses clinical, spirometric and radiographic findings to help delineate if an adult patient is
most likely suffering from asthma or COPD or fulfills enough shared features to be considered
within ACOS. This definition and the diagnostic criteria differ from other guidelines, for
instance, the Spanish expert report from 2012 [10].
The different diagnostic criteria proposed so far are discussed in Section 5. However, to obtain
any clearer and validated criteria, further research about underlying mechanisms is needed.
3. Prevalence of ACOS
The exact prevalence of ACOS is unknown. In general, the literature on ACOS has been mostly
retrospective and observational, and the studies focused on asthma or COPD populations. It
is well known that studies on asthma are usually performed in populations of children or
young adults, where the prevalence of COPD is negligible, whereas studies on COPD are
usually performed in elderly populations, where the prevalence of asthma is low. The
COPDGene study found a prevalence of 13% of ACOS [2]. These patients may have a different
clinical natural history, with more frequent and severe exacerbations (odds ratio [OR] 3.55),
and different treatment response, which led to recommend early introduction of inhaled
corticosteroids (ICS) in these patients. These figures are similar to those reported in the
PLATINO study [11]: 12% prevalence for the ACOS phenotype and more risk of exacerbations
in these patients (OR 3.01). The inconsistencies and discrepancies that exist upon reported data
on prevalence can be in part explained by the absence of a consistent definition and diagnostic
standards. In comparison to previous studies that have considered selected groups of patients,
such as COPD patients, the study published by de Marco et al [12] assessed the prevalence of
ACOS in the general population. They found that this prevalence ranged from a minimum of
1.6% (95% confidence interval (CI): 1.3%–2.0%) in the 20–44 years old age group to 4.5% (95%
CI: 3.2%–5.9) in the 60–84 years old age group.
4. Pathogenic mechanisms
Several potential pathways might lead to the presentation of ACOS in adults. One such
pathway begins in early-onset asthma. Smoking habit later in life might lead to development
of fixed airflow limitation and COPD in many of these patients. A second potential pathway
recognizes patients with a lifetime smoking history, subsequent COPD, and late-onset features
of asthma (adult-onset eosinophilic asthma and aspirin-exacerbated respiratory disease) (see
also Figure 1).
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Figure 1. Pathogenic pathways leading to ACOS development.
Although no previous studies have addressed the underlying mechanisms of inflammation in
ACOS, there is convincing evidence that eosinophils play a pivotal role, similar to what it is
found in asthma with a Th2-high profile. Different studies have demonstrated that the presence
of significant eosinophilia in an induced sputum sample predicts a good response to ICS, both
in patients with COPD and ACOS [13–15]. On the other hand, the presence of more number
of neutrophils in sputum has been recently associated with a worse prognosis in asthmatics
[16]. Since both asthma and COPD are inflammatory diseases that affect the bronchial tree, it
is to be expected to find, in patients with ACOS, some evidence of the Th-1 pattern (charac‐
teristic of COPD) and some evidence of Th-2 pattern (characteristic of asthma). The current
search for reliable biomarkers of Th1 and Th2 inflammation hopefully will provide additional
information in the upcoming years.
Previous studies defined two new asthma molecular phenotypes, namely Th2 high and Th2
low [17]. The Th2–high gene signature includes chloride channel accessory protein 1 (CLCA1),
SERPINB2, and periostin (encoded by POSTN), a secreted 90-kDa extracellular matrix protein
that is induced by interleukin (IL)-4 and IL-13 in airway epithelial cells and lung fibroblasts.
All three genes are induced in bronchial epithelial cells by recombinant IL-13 treatment in
vitro, and the expression of these genes correlates with IL-13 and IL-5 expression in the
bronchial mucosa, airway and peripheral eosinophilia, airway remodeling, and clinical
responsiveness to ICS treatment, but not with atopy. Even more so, periostin seems to become
an emerging noninvasive biomarker associated with eosinophilic inflammation, Th2-high
molecular phenotype, and airway remodeling, and has potential utility in patient selection for
emerging asthma therapeutics targeting Th2 inflammation. A study by Jia et al. [18] identified
serum periostin as a systemic biomarker of airway eosinophilia in severe, uncontrolled
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asthmatics belonging to the BOBCAT cohort (Bronchoscopic Exploratory Research Study of
Biomarkers in Corticosteroid-refractory Asthma). In a logistic regression model, serum
periostin was the single best predictor of sputum and tissue eosinophilia, showing superiority
to blood eosinophils, IgE, and FeNO. Mean periostin levels were significantly higher in
“eosinophil-high” when compared with “eosinophil-low” patients, as defined by sputum or
tissue eosinophil measurements. Using 25 ng/mL serum periostin as an arbitrary cutoff,
eosinophil-low and eosinophil-high patients from the BOBCAT study were effectively
differentiated, with a positive predictive value of 93% [18]. Moreover, in 62 patients diagnosed
with severe asthma, Bobolea et al. [19] found that periostin levels were higher in patients with
fixed airflow limitation than in patients with variable airflow limitation (69.76 vs 43.84 ng/ml,
p < 0.05) and in patients with eosinophilic phenotype than in patients with mixed granulocytic
phenotype (61.58 vs 37.31 ng/ml, P < 0.05). However, in a cohort of patients with a broad
spectrum of asthma severities, Wagener et al. [20] found that blood eosinophils had the highest
accuracy in the identification of sputum eosinophilia. In this study, serum periostin was not
able to distinguish eosinophilic from noneosinophilic airway inflammation. Therefore, in view
of the differing positions, the exact role of periostin in the diagnosis of Th2 bronchial inflam‐
mation remains to be determined.
5. Diagnosis of ACOS
The specific criteria for diagnosis of this special syndrome had never been established until
2012, when an expert panel meeting of Spanish key opinion leaders agreed unanimously to
confirm the existence of this patient profile and to establish a set of criteria for its diagnosis [10],
which has been posteriorly adapted within the Spanish COPD Guideline, although not yet
validated. The initial definition of ACOS proposed by the Spanish consensus group is as
follows: the diagnosis of ACOS is made when two major criteria or one major and two minor
criteria are met. The major criteria include a very positive bronchodilator (BD) test (increase
in forced expiratory volume in 1 second [FEV1] >15% and >400 mL), eosinophilia in sputum,
and personal history of asthma. Minor criteria include high total IgE, personal history of atopy,
and positive BD test (increase in FEV1 >12% and >200 mL) on two or more occasions.
The new Finnish guidelines for the treatment of COPD proposed the same criteria for the
diagnosis of ACOS as the Spanish guidelines, with the addition of an elevated FeNO higher
than 50 parts per billion as a major criterion and a peak flow follow-up typical for asthma as
an additional minor criterion [21]. The latest Czech Republic guidelines, published in 2013,
also include ACOS with its own diagnostic criteria, similar to the Spanish recommendations
[22]. These are, however, quite restrictive criteria and represent a very conservative approach
until more evidence about the characterization of ACOS becomes available from large clinical
trials or prospective studies. In fact, two recent studies in Spain, using the previous criteria,
identified that only between 5% and 6% of the patients fulfilled the criteria for ACOS, in
patients with smoking-related COPD [23, 24]. This percentage is clearly below the expected
number of individuals sharing the characteristics of asthma and COPD, according to epide‐
miological data.
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In fact, in a Spanish survey performed among pulmonology specialists, selected as experts in
asthma and COPD, aimed at collecting their opinions about ACOS and their attitudes in regard
to some case scenarios of ACOS patients, only 34.6% of the specialists surveyed were in
agreement with the Spanish criteria, and 30.8% were in an intermediate position between
agreement and disagreement. The main aspect highlighted by 76.9% of the specialists was that
these criteria had to be validated in prospective studies [25].
On the other hand, the GINA–GOLD approach to diagnosis of ACOS [9] is deliberately
descriptive and perhaps not very suitable for clinical applications, but recognizes that this
entity, just like asthma and COPD, comprises a heterogeneous group of disorders.
The characteristics that might support the diagnosis of ACOS according to GINA–GOLD are
as follows:
1. – Usually age 40 years or older, but may report symptoms in childhood or early adulthood.
2. – Respiratory symptoms, including exertional dyspnea, are persistent, but variability may
be prominent.
3. – Airflow limitation that is not fully reversible, but often with evidence of significant
current or historical variability.
4. – Persistent airflow limitation.
5. – Frequently, a history of doctor-diagnosed asthma (current or previous), allergies and a
family history of asthma, and/or a history of noxious exposures, as seen in COPD.
6. – Symptoms are partly but significantly reduced by treatment. Progression is usual, and
treatment needs are high.
7. – Exacerbations may be more common than in COPD, but are reduced by treatment.
8. – Comorbidities can contribute to clinical and functional impairment.
9. – COPD-like findings on the chest X-ray.
10. – Typically eosinophilia (with or without associated neutrophilia) in sputum.
Taking into consideration all these previously proposed criteria, the most recent Spanish
guideline on the management of asthma (GEMA 2015) [26] proposes an algorithm designed
to guide physicians in their routine clinical practice. The existence of patients who fulfill the
criteria for COPD – adult smokers with respiratory symptoms and post-BD FEV1/FVC <0.7 –
and who present characteristics of asthma, such as high reversibility of airflow, signs of
bronchial and systemic eosinophilic inflammation, history of atopy, or even a previous
diagnosis of asthma before the age of 40 years, has been definitely recognized. This approach
also includes, as a novelty when compared with all the others, an oral corticosteroid test with
prednisone to assess reversibility of the bronchial obstruction. If FEV1/FVC remains below
70% after a BD test, a methacholine test and the presence or absence of biomarkers of Th2
inflammatory response should help the clinician to distinguish between COPD and ACOS [17].
The algorithm is summarized in Figure 2.
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Figure 2. Diagnostic algorithm for ACOS according to GEMA 2015 [26].
BD-test: bronchodilator test; eos: eosinophils.
6. Prognostic implications
It has been reported that patients with ACOS have more frequent exacerbations, are more likely
to have a severe exacerbation requiring hospitalization, use more respiratory medications, and
have the highest reported pulmonary symptoms. More importantly, patients with ACOS also
report worse quality of life than those with either disease alone [27, 28].
However, other authors found that the ACOS phenotype was not clinically different at
baseline, in other than the specific criteria used to define it, than patients with no criteria for
ACOS. Interestingly, survival after 1 year of follow-up was significantly better in patients with
ACOS [29]. To explain such a discrepancy, it should be mentioned that this population
included 72% of patients with mild-to-moderate disease, which differs from previous publi‐
cations with more severe COPD, and of note, 63% of patients with ACOS were receiving ICS,
which likely contributed to ameliorate the clinical differences, when compared to the non-
ACOS group.
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The prognostic significance of having a diagnosis of ACOS must be further assessed in the
light of a prospective cohort study, designed to compare the outcomes of COPD patients,
asthmatics, and individuals with both diseases.
7. Treatment of ACOS
The present approach to pharmacotherapy for ACOS includes trial and error and extrapolation
from results of investigations, in particular subpopulations of asthma or COPD patients. The
first option recommended by the Spanish consensus guideline for patients with overlap
phenotype COPD-asthma is to add ICS to the treatment for COPD [10], as it is also indicated
in the Finnish and Czech guidelines [21, 22]. The GINA–GOLD document also indicates that
the default position in the case of ACOS should be to start treatment accordingly for asthma,
and recommends the LABA/ICS combination, with special attention to avoid the use of LABAs
in monotherapy. In the Spanish survey among expert pulmonologists mentioned before [25],
88.5% of the participants agreed that ACOS requires a different treatment compared to COPD,
starting with LABA/ICS and stepping up to triple therapy (LABA/ICS+LAMA) in severe cases.
However, these and other recommendations are not based on high-quality data, because
patients with ACOS have been classically excluded from pharmacological clinical trials both
in asthma and in COPD. As a consequence, there is no clear information about the response
of these patients to most of the current pharmacological therapies. The only clinical trial
performed to date in patients with ACOS studied the spirometric effects of tiotropium in
individuals with concomitant COPD and asthma. Improvement in lung function and a
reduction in rescue medication were observed with tiotropium [30].
However, the main interest in differentiating ACOS from COPD lies in the different response
to ICS.
Kitaguchi et al. [15], in a retrospective study with a small sample size, found that COPD
patients with asthmatic symptoms had high peripheral and sputum eosinophil counts and
better reversibility response to treatment with ICS. These findings reproduce those of other
studies, in which COPD patients with a positive BD test, or with a positive hyperreactivity
test, or with sputum eosinophilia, have been shown to be more responsive to ICS than those
without these features [31–36]. Therefore, it seems logical to consider ICSs as the cornerstone
of treatment in ACOS with the addition of long-acting β-agonists in those patients who remain
symptomatic or suffer recurrent exacerbations.
In addition to the only clinical trial of Magnussen et al., more recent literature has demonstrated
the efficacy of long-acting muscarinic antagonists (LAMA), such as tiotropium, in people with
asthma with persistent bronchial obstruction [37, 38]. With all these recent data in mind, the
Spanish guideline GEMA 2015 recommends the combination of an ICS with a long-acting β-
agonist as the first therapeutic choice in patients with ACOS, leaving open the option to add
a LAMA if the patients remain uncontrolled [26].
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Biological treatments that target Th2-related pathways (omalizumab, anti–IL-5, and perhaps
anti–IL-4/-13) might also be effective in ACOS, and they warrant further investigation. This is
also the case for drugs that target predominantly neutrophil-driven mechanisms, such as
roflumilast.
8. Discussion: ACOS as a phenotype or endotype of obstructive airway
disease.
Asthma and COPD are themselves heterogeneous disorders that comprise several phenotypes
and endotypes. If we admit that ACOS should be characterized by the presence of inflamma‐
tory features of both COPD (mainly Th1) and asthma (mainly Th2), we could argue that COPD
patients with sputum eosinophilia and with asthma, with a mixed neutrophilic–eosinophilic
pattern are, in fact, patients with ACOS, regardless of their clinical presentation. So changing
our point of view, from an initial clinically based classification of obstructive airways diseases
to another centered on inflammatory underlying mechanisms (endotypes), would allow us to
tailor and optimize treatments, leaving behind the rigid categorization of patients into existing
diagnostic labels of either asthma or COPD, which do not fully recognize the molecular and
clinical heterogeneity of chronic obstructive airway diseases [39].
We need to move toward a new taxonomy of airway diseases that takes into account the
underlying pathogenic mechanisms. In this new scenario, ACOS would be an endotype, like
early-onset allergic asthma or emphysema. However, things are not so straightforward, and
there are several important issues that complicate the settling-in of this new approach:
• Sputum cell count, the method of reference to measure and identify bronchial inflammation,
is technically complex and time consuming. At this moment, we do not have substitute
reliable biomarkers to identify the bronchial underlying inflammatory mechanisms in a
particular patient.
• There is not a complete identification between a particular and well-recognized clinical
phenotype (e.g. late-onset eosinophilic asthma) and an exclusive inflammatory pattern (e.g.
eosinophilic). In a large cross-sectional study of patients with airway disease, D’Silva et al.
[40] reported the cellular profile of over 4,000 induced or spontaneous sputum samples. In
the ACOS group, eosinophilic bronchitis was seen in 35%, neutrophilic bronchitis in 19%,
and a mixed inflammatory pattern in 10%. In COPD, the phenotypes were respectively 18%,
34%, and 7% and, in asthma alone, 26%, 14%, and 6%. These data bring to the table the
heterogeneous nature of airway inflammation in asthma and COPD.
• The inflammatory pattern can vary over time, either spontaneously or as a result of
treatment.
It is to be expected that in a near future, advances in the identification of inflammatory patterns
can help us to adequately classify patients with chronic obstructive airway disease and offer
them the best therapeutic option in each case.
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9. Conclusions
ACOS is the coincidence of asthma and COPD in the same individual. Prospective studies are
required to analyze the underlying inflammatory mechanisms in this entity. So we think that
longitudinal studies are required to validate the diagnostic criteria and identify biomarkers of
the disease. It also remains to be determined if it has different prognostic and therapeutic
implications. If so, perhaps in the future, ACOS will be considered a distinct endotype of
chronic obstructive airway disease. There is also a lack of studies to further clarify the best
therapeutic options for patients with ACOS. At this moment, it seems reasonable to consider
the combination of an ICS and a long-acting β-agonist as the first-choice therapy for these
patients.
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